Uitgebreid zoeken
Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
E-mailregistratie
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Australië
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. Nieuws
  7. Persberichten
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Rapport
Vertraagde tijd Australian Stock Exchange  -  06:10:36 30-01-2023
3.200 AUD   -6.43%
18/01MAYNE PHARMA GROUP LIMITED : REVERSE SPLIT: 1 voor 20
FA
18/01MAYNE PHARMA GROUP LIMITED : Onthechting van dividenddividend (uitzonderlijk)
FA
13/01Weer winst in Brussel
AM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société MAYNE PHARMA GROUP LIMITED
16/01Mayne Pharma and Mithra announce US launch of HALOETTE, a generic version of NUVARING
AQ
2022Mayne pharma completes sale of metrics contract services
AQ
2022Mayne pharma - appointment of chief executive officer and managing director
AQ
2022Mayne pharma group - non-executive director appointment and retirement
AQ
2022Mayne Pharma : CEO announces plan to retire
PU
2022Mayne Pharma : announces sale of Metrics Contract Services
PU
2022Mayne Pharma : and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
PU
2022Mayne pharma and goodrx announce new initiative to increase awareness of nextstellis an..
AQ
2022Mayne Pharma Group Limited and Mithra Pharmaceuticals - NEXTSTELLIS ORAL CONTRACEPTIVE ..
AQ
2022Mayne Pharma : New Chief Financial Officer appointment
PU
2022Mayne Pharma : Wilsons investor conference presentation
PU
2022Mayne pharma announced as recipient of $4.8m federal government grant
AQ
2022Mayne Pharma Group Limited - NON-EXECUTIVE DIRECTOR APPOINTMENT
AQ
2022Mayne Pharma : 22/03/2022 Non Executive Director Appointment
PU
2022Mayne pharma reports 1hfy22 results
AQ
2022Mayne Pharma : 2022 Half Year Investor Presentation
PU
2022Mayne Pharma : 25/02/2022 Mayne Pharma 2022 Half Year Results Media Release
PU
2022Mayne pharma expands us dermatology portfolio
AQ
2022Mayne Pharma : 10/02/2022 Mayne Pharma expands US dermatology portfolio
PU
2022Mayne Pharma - NON-EXECUTIVE DIRECTOR APPOINTMENT AND RETIREMENT
AQ
2022Mayne Pharma : 17/01/2022 Non-Executive Director appointment and retirement
PU
2022Mayne Pharma : 12/01/2022 Mayne Pharma adds a generic PROTOPIC to US portfolio
PU
2021Mayne Pharma : Change of Director's Interest Notice
PU
2021Mayne Pharma : Notification regarding unquoted securities - MYX
PU
2021Mayne pharma and mithra announce tga approval of nextstellis oral contraceptive
AQ
2021Mayne Pharma : Notification of cessation of securities - MYX
PU
2021Mayne Pharma : 29/11/2021 TGA approval of novel oral contraceptive NEXTSTELLIS
PU
2021Mayne Pharma : 23/11/2021 2021 AGM Chairman's Address
PU
2021Mayne Pharma : 23/11/2021 2021 AGM CEO's Speech
PU
2021Mayne Pharma : 2021 Mayne Pharma AGM Speeches
PU
2021Mayne Pharma : 23/11/2021 2021 Mayne Pharma AGM Speeches
PU
2021Mayne Pharma : 2021 Corporate Governance Statement and Appendix 4G
PU
2021Mithra Pharmaceuticals S A : Provides FDA Update on Myring
AQ
2021Mayne Pharma : Provides fda update on generic nuvaringo
AQ
2021Mayne Pharma : 07/10/2021 Mayne Pharma provides FDA update on generic NUVARING
PU
2021Mithra Pharmaceuticals S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
2021Mayne Pharma : appoints new Director
PU
2021Mayne Pharma : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
AQ
2021Mayne Pharma : Adds generic absorica to us dermatology portfolio
AQ
2021Mayne Pharma : 29/09/2021 Mayne Pharma adds generic ABSORICA® to US portfolio
PU
2021Mayne Pharma : Notification regarding unquoted securities - MYX
PU
2021Mayne Pharma : Fda approves lexetteo for adolescent plaque psoriasis
AQ
2021Mayne Pharma : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
2021Mayne Pharma : Change of Director's Interest Notice
PU
2021Mayne Pharma : 2021 Full Year Media Release
PU
2021Mayne Pharma : 2021 Full Year Investor Presentation
PU
2021Mayne Pharma : Appendix 4E and Statutory Accounts
PU
2021Mayne Pharma : 27/08/2021 Mayne Pharma 2021 Full Year Results Media Release
PU
2021Mayne Pharma : board renewal and new Chairman
PU
2021Mayne Pharma : Class action proceeding
AQ
2021Mayne Pharma : 03/08/2021 MYX - Class action proceeding
PU
2021Mayne Pharma : Notification of cessation of securities - MYX
PU
2021Mayne Pharma : Change of Director's Interest Notice
PU
2021Estelle Oral Contraceptive Now Available In the United States
AQ
2021Mayne Pharma : 21/06/2021 Nextstellis® Oral Contraceptive Now Available in the United Stat..
PU
2021Mayne Pharma : 21/06/2021 Mayne Pharma Expands Australian Dermatology Portfolio
PU
2021Mayne - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Published
AQ
2021Mayne Pharma : Nextstellis receives fda marketing exclusivity and phase iii data published
AQ
2021Mayne Pharma : 27/05/2021 Nextstellis® Receives FDA Marketing Exclusivity and Phase III Da..
PU
2021Mayne Pharma : Appendix 2A and Notice under ASX Listing Rule 3.10A
PU
2021Mayne Pharma : 16/04/2021 u.s. fda approves nextstellis®, new oral contraceptive
PU
2021Mayne Pharma : And mithra announce fda approval of new oral contraceptive nextstellis
AQ
2021Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle
AQ
2021Mayne Pharma : 16/04/2021 FDA approval of novel oral contraceptive NEXTSTELLIS
PU
2021Mayne Pharma : 08/03/2021 New data on NEXTSTELLIS presented at ISSWSH conference
PU
2021Mayne Pharma : 2021 Half Year Results Media Release
AQ
2021Mayne Pharma : 24/02/2021 Mayne Pharma 2021 Half Year Results Media Release
PU
2021Mayne Pharma : launches Microgestin 24 FE tablets in the US
PU
2021Mayne Pharma : 07/01/2021 Mayne Pharma launches Microgestin® 24 Fe tablets in the United S..
PU
2020Mayne Pharma : 18/12/2020 Mayne Pharma successfully extends debt facility
PU
2020Mayne Pharma : successfully extends debt facility
PU
2020Mayne Pharma : 24/11/2020 2020 AGM Chairman's Address
PU
2020Mayne Pharma : 24/11/2020 2020 AGM CEO's Speech
PU
2020Mayne Pharma : 09/11/2020 Mayne Pharma Board Renewal
PU
2020Mayne Pharma : Board Renewal
PU
1  2  3  4Volgende
Volgende evenement op MAYNE PHARMA GROUP LIMITED
24/02/23Eerste halfjaar 2023 Cijferpublicaties
Komende gebeurtenissen in de sector
31/01/23ONO PHARMACEUTICAL CO., LTD. : Q3 2022 Cijferpublicaties
31/01/23SUN PHARMACEUTICAL INDUSTRIES LIMITED : Q3 2023 Cijferpublicaties
14/02/23OTSUKA HOLDINGS CO., LTD. : Boekjaar 2022 Cijferpublicaties
28/03/23SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. : Boekjaar 2022 Cijferpublicaties
Sector
Gezondheidszorg
Farmaceutisch en medisch onderzoek
 Farmaceutische producten
  Farmaceutische producten
   Generieke geneesmiddelen